BioCentury | Mar 4, 2020
Finance

March 3 Quick Takes: Megarounds for Akouos, Element; plus venture rounds by Kahr, Primmune, Lipidio and Scipio and more

...Signaling Proteins platform, the molecule targets SIRPA and 4-1BBL to treat solid tumors. Investors include Flerie Invest AB...
BioCentury | Oct 17, 2019
Financial News

Oct. 16 Financial Quick Takes: Hong Kong IPO could value Ascentage at $876M; plus Principia, Rhythm, ProQR, dMed, Ionova and Amarna

...SVac, its Simian Virus 40-based gene delivery vector platform, to the clinic within three years. Flerie Invest AB...
BioCentury | Dec 21, 2015
Financial News

Kahr Medical completes venture financing

...Venture financing Raised: $12 million Investors: Korea Investment Partners; Mirae Asset Venture Investment; DSC Investment; Flerie Invest AB...
Items per page:
1 - 3 of 3
BioCentury | Mar 4, 2020
Finance

March 3 Quick Takes: Megarounds for Akouos, Element; plus venture rounds by Kahr, Primmune, Lipidio and Scipio and more

...Signaling Proteins platform, the molecule targets SIRPA and 4-1BBL to treat solid tumors. Investors include Flerie Invest AB...
BioCentury | Oct 17, 2019
Financial News

Oct. 16 Financial Quick Takes: Hong Kong IPO could value Ascentage at $876M; plus Principia, Rhythm, ProQR, dMed, Ionova and Amarna

...SVac, its Simian Virus 40-based gene delivery vector platform, to the clinic within three years. Flerie Invest AB...
BioCentury | Dec 21, 2015
Financial News

Kahr Medical completes venture financing

...Venture financing Raised: $12 million Investors: Korea Investment Partners; Mirae Asset Venture Investment; DSC Investment; Flerie Invest AB...
Items per page:
1 - 3 of 3